NCT06365814Completed
ERAS for Gastric Cancer Patients After NACT
Short- and Long-term Outcomes Following Perioperative ERAS Management in Patients Undergoing Minimally Invasive Radical Gastrectomy After Neoadjuvant Chemotherapy: A Single-center Retrospective Propensity Score Matching Cohort Study
Source: ClinicalTrials.gov · Last updated 15 Apr 2024
Brief summary (registry, in English)
Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress responses. However, whether this approach is safe and feasible for gastric cancer patients received minimally invasive radical gastrectomy after NACT remained determined. So, the objective of this study is to investigate the effects of ERAS for this special group of gastric cancer patients. Materials and Methods: The data of gastric cancer patients who underwent minimally invasive radical gastrectomy after NACT were collected in this retrospective cohort study. Patients were divided into an ERAS group and a conventional group based on whether they received perioperative ERAS management. Propensity score matching was conducted to eliminate bias. Pre- and postoperative inflammatory and nutritional marker levels, postoperative complications, recovery indices and 3-year OS and RFS were observed.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 252 (actual)
- First submitted
- 9 Apr 2024
- Start date
- 1 Oct 2023
- Primary completion date
- 1 Apr 2024
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06365814
What you commit to
- Study type: Observational
- Participants enrolled: 252
- From 1 Oct 2023 to the primary completion date, 1 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- inability to complete the planned preoperative chemotherapy,
- infeasibility of performing radical gastrectomy during surgery
Other illness
- conversion to open surgery due to intraoperative difficulties or uncontrolled complications (for example, intraoperative massive bleeding),
Other
- ERAS item implementation rate less than 60%
Who the study is looking for
- gastric adenocarcinoma confirmed by histopathology,
- received 2 to 4 cycles of NACT before surgery,
- minimally invasive (DaVinci or laparoscopy) radical gastrectomy with D2 lymph node dissection
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital Coordinator of this site? Confirm its status | Qingdao | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.